Pluvicto (lutetium vipivotide tetraxetan)
pCPA File Number: 22315
For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.
Advanced Accelerator Applications
CADTH Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: